Indocyangreen Elimination in Cirrhosis and Acute Liver Failure
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00245310|
Recruitment Status : Completed
First Posted : October 27, 2005
Last Update Posted : October 11, 2010
Indocyangreen (ICG)is totally biliary eliminated and corresponds to hepatocyte function and liver perfusion.
The ICG-clearance will be evaluated as a prognostic marker in liver disease.
|Condition or disease||Intervention/treatment|
|Acute Liver Failure Liver Cirrhosis||Procedure: Indocyangreen (ICG) clearance|
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||Evaluation of the Indocyangreen Elimination as a Prognostic Marker in Decompensated Cirrhosis and Acute Liver Failure|
|Study Start Date :||October 2005|
|Actual Primary Completion Date :||October 2010|
|Actual Study Completion Date :||October 2010|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00245310
|University of Heidelberg|
|Heidelberg, Germany, 69120|
|Principal Investigator:||Jens Encke, PD Dr. med.||Heidelberg University|